Management of diabetes with glucose sensors and implantable insulin pumps: From the dream of the 60s to the realities of the 90s

ASAIO Journal

Volumn 43, Issue 3, 1997, Pages 137-142

  Selam, J L ^a  

^a HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMEDICAL ENGINEERING; ENDOCRINOLOGY; GLUCOSE SENSORS; HEALTH CARE; IMPLANTS (SURGICAL); INSULIN; MEDICINE;

DIABETES; INSULIN PUMPS;

DRUG INFUSION;

GLUCOSE; INSULIN;

ARTIFICIAL PANCREAS; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HISTORY OF MEDICINE; HUMAN; HUMAN TISSUE; HYPOGLYCEMIA; IMPLANT; INSULIN PUMP; REVIEW; SENSOR; TREATMENT OUTCOME;

EID: 0342711183     PISSN: 10582916     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002480-199705000-00004     Document Type: Review

References (69)

1. Kadish AH: Automation control of blood sugar. I. A servomechanism for glucose monitoring and control. Am J Med Elect 82-86, 1964.
2. Albisser AM, Leibel BS, Ewart TG, et al: Clinical control of diabetes by the artificial pancreas. Diabetes 23: 397-404, 1974.
3. Clemens AH: The artificial endocrine pancreas. A model system for computerized feedback control instrumentation. Miles Analecta 2:4-8, 1975.
4. Pfeiffer EF, Thum Ch, Clemens AH: The artificial betacell. A continuous control of blood sugar by external regulation of insulin infusion (glucose controlled insulin infusion system). Horm Metab Res 6: 339, 1974.
5. Mirouze J, Selam JL, Pharm TC, Cavadore D: Evaluation of exogenous insulin homeostasis by the artificial pancreas in insulin-dependent diabetes. Diabetologia 13: 273-278, 1977.
6. Shichiri M, Kawamori R: The artificial endocrine pancreas. Device for the control of diabetes mellitus. MA News IV: 10-22, 1983.
7. Heinemann L, Berger M, Bocker D, et al: Continuous non-invasive glucose monitoring in type I diabetic patients. 56th Meeting of ADA, San Francisco, 1996. Diabetes 45(suppl. 2): 221A, 1996. (Abstract)
8. Rosenthal RD, Paynter LN: A portal non-invasive blood glucose meter. Diabetes 40(suppl. 1): 312A, 1991. (Abstract)
9. Gough DA, Leypoldt JK, Armour JC: Progress toward a potentially implantable enzyme-based glucose sensor. Diabetes Care 5: 190-198, 1982.
10. Velho G, Reach G, Thevenot DR: The design and development of in vivo glucose sensors for artificial endocrine pancreas. In: Turner APF, Karube L, Wilson GS, eds. Biosensors. Oxford, UK, Oxford University Press, 1987, 390-408.
11. Shichiri M, Kawamori R, Yamasaki Y, Hakui N, Abe H: Wearable artificial endocrine pancreas with needle-type glucose sensor. Lancet 1: 1129-1131, 1982.
12. Fischer U, Ertle R, Rebrin K, Freyse EJ: Wick technique: reference method for implanted glucose sensors. Artificial Organs 83: 453-457, 1989.
13. Mastrototaro JJ, Van Antwerp WP, Mestman J: Preliminary clinical evaluation of a new subcutaneous glucose sensor. 9th Biennial ISGIID Meeting, abstract, June 12-13, 1996, Meadowood, CA.
14. Sternberg F, Hoss U, Mennel FJ, Salgado M, Pfeiffer EF: Novel method to monitor the s.c. glucose in man: advantages of the enzyme addition over the GOD immobilization. Diabetes 45(suppl. 2): 140A, 1996. (Abstract)
15. Poitout V, Moatti-Sirat D, Reach G, et al: A glucose monitoring system for in line estimation in man of blood glucose concentration using a miniaturised glucose sensor implanted in the subcutaneous tissue, and a wearable control unit. Diabetologia 36: 658-663, 1993.
16. Pfeiffer EF, Meyerhoff C, Bischof F, Keck FS, Kerner W: On line continuous monitoring of subcutaneous tissue glucose is feasible by combining portable glucosensor with microdialysis. Horm Metab Res 25: 121 -124, 1993.
17. Shichiri M, Sakakida M, Hashiguchi Y, Nishida K: Development of subcutaneous insulin infusion algorithm using rapid acting insulin analogue for long-term application of wearable artificial endocrine pancreas. 9th Biennial ISGIID Meeting. 1996, abstract, June 12-13, 1996, Meadowood, CA.
18. Moatti-Sirat D, Poitout V, Thome V, et al: Reduction of acetaminophen interference in glucose sensors by a composite Nafion membrane: demonstration in rats and man. Diabetologia 37: 610-616; 1994.
19. Schmidt FJ, Sluiter WJ, Schoonen AJM: Glucose concentration in subcutaneous extracellular space. Diabetes Care 16: 695-700, 1993.
20. Thome-Duret V, Reach G, Gangnereau MN, et al: The decrease in subcutaneous glucose concentration precedes the decrease in blood glucose level, following insulin administration. Implications for the development of a hypoglycaemic alarm using a subcutaneous glucose sensor. Ann Chem (in press).
21. Blackshear PH, Rohde TD, Grotting JC, et al: Control of blood glucose in experimental diabetes by means of a totally implantable insulin infusion device. Diabetes 28: 634-639, 1979.
22. Blackshear PH, Dorman FD, Blackshear PL Jr, Varco RL, Buchwald H: Permanently implantable self-recycling low-flow constant-rate multipurpose infusion pump of simple design. Surg Forum 21: 136-137, 1971.
23. Irsigler K, Kritz H, Hagmüller G, et al: Long-term continuous intra-peritoneal insulin infusion with an implanted remote-controlled insulin infusion device. Diabetes 30: 1072-1075, 1981.
24. Point study group: On-year trial of a remote-controlled implantable insulin infusion system in type I diabetic patients. Lancet 1: 866-869, 1988.
25. Saudek CD, Selam JL, Pitt HA, Waxman K, Fischell RE, Charles MA: A preliminary trial with the programmable implantable medication system for insulin delivery. N Engl J Med 321: 574-579, 1989.
26. Selam JL, Micossi P, Dunn FL, Nathan DV: Implantable insulin pump trial study group: Clinical trial of programmable implantable insulin pump for type I diabetes. Diabetes Care 15: 877-885, 1992.
27. Selam JL, Zirinis PH, Mellet M, Mirouze J: Stable insulin for implantable delivery systems: in vitro studies with different containers and solvents. Diabetes Care 10: 343-347, 1987.
28. Grau U: Chemical stability of insulin in a delivery system environment. Diabetologia 29: 458-463, 1985.
29. Selam JL, Zirinis PH, Bardin C, Deverdjian S, Franck B: Evaluation of physical stability of lispro insulin for pumps. 9th Biennial ISGIID Meeting (abstract).
30. Wredling R, Liu D, Lins PE, Adamson U: Variation of insulin absorption during subcutaneous and peritoneal infusion in insulin-dependent diabetic patients with unsatisfactory long-term glycaemic response to continuous subcutaneous insulin infusion. Diabet Metab 17: 456-459, 1991.
31. Schade D, Eaton RP, Friedman N, Spencer W: The intravenous intraperitoneal and subcutaneous routes of insulindelivery in diabetic man. Diabetes 38: 1069-1073, 1979.
32. Schade D, Eaton RP, Davis T, et al: The kinetics of peritoneal insulin absorption. Metabolism 30: 149-155, 1981.
33. Micossi P, Cristallo M, Librenti MC, et al. Free-insulin profiles after intraperitoneal, intramuscular, and subcutaneous insulin administration. Diabetes Care 9: 575-578, 1986.
34. Selam JL, Raymond M, Jacquemin JL, Orsetti A, Richard JR, Mirouze J: Kinetics of insulin infused intraperitoneally via portable pumps. Diabet Metab 11: 170-173, 1985.
35. Lassmann-Vague V, Belicar P, Alessis C, Raccah D, Vialettes B, Vague P: Insulin kinetics in type I diabetic patients treated by continuous intraperitoneal insulin infusion: influence of anti-insulin antibodies. Diabetic Medicine 13: 1051-1055, 1996.
36. Nathan DN, Dunn FL, Bruch J, et al: Postprandial insulin profiles with implantable pump therapy may explain decreased frequency of severe hypoglycemia, compared with intensive subcutaneous regimens, in insulin-dependent diabetes mellitus patients. Am J Med 100: 412-417, 1996.
37. De Vos P, Vegter D, De Haan BJ, Strubbe JH, Bruggink JE, Vanschilgaarde R: Kinetics of intraperitoneally infused insulin in rats. Functional implications for the bioartificial pancreas. Diabetes 45: 1102-1107, 1996.
38. Selam JL, Bergman RN, Jean-Didier N, Lozano J, Charles MA: Determination of portal insulin asborption from peritoneum via novel nonisotopic method. Diabetes 39: 1361-1365, 1990.
39. Rizza R, Westland RE, Hall LD, et al. Effects of peripheral versus portal venous administration of insulin on post-prandial hyperglycémia and glucose turnover in allox-an-diabetic dogs. Mayo Clinic Proc 56: 434-438, 1981.
40. Stevenson RW, Parsons JA, Alberti KGMM: Effect of intraportal and peripheral insulin on glucose turnover and recycling in diabetic dogs. Am J Physiol 244: E190-E195, 1983.
41. Ishida T, Chap Z, Chou J, Lewis RM, Entman ML, Field JB: Effects of portal and peripheral venous insulin infusion on glucose production and utilization in depancreatized conscious dogs. Diabetes 33: 984-990, 1984.
42. Ader M, Bergman RN: Peripheral effects of insulin dominate suppression of fasting hepatic glucose production. Am J Physiol 258: E1020-E1032, 1990.
43. Bouhanick B, M'Bemba J, Robert JJ, Rongier M, Slama G, Selam JL: Effects of peritoneal vs peripheral venous insulin delivery on glucose production and utilization in type I diabetic patients. Diab Nutr Metab 7: 213-218, 1994.
44. Kryshak EJ, Butler PC, Marsh C, et al: Pattern of postprandial carbohydrate metabolism and effets of portal and peripheral insulin delivery. Diabetes 39: 142-147, 1990.
45. Ducasse M, Selam JL, Tauber JP, Mirouze J, Bayard F: Comparative study of insulin-resistance during intraperitoneal and intravenous insulin administration in diabetic patients. Diab Metab 32: 326A, 1985.
46. Lewis GF, Zinmann B, Groenewoud Y, Vranic M, Giacca A: Hepatic glucose production is regulated both by direct hepatic and extrahepatic effects of insulin in humans. Diabetes 45: 454-462, 1996.
47. Selam JL, Medlej R, M'Bemba J, et al: Symptoms, hormones and glucose fluxes during a gradual hypoglycaemia induced by intraperitoneal vs venous insulin infusion in type I diabetes. Diabetic Medicine 12: 1102-1109, 1995.
48. Selam JL, Kashyap M, Alberti KGMM, et al: Comparison of intraperitoneal and subcutaneous insulin administration on lipids, apolipoproteins, fuel metabolites, and hormones in type I diabetes mellitus. Metabolism 38: 908-912, 1989.
49. Selam JL, Kashyap ML, Gupta AK, et al: Alterations in reverse cholesterol transport associated with programmable implantable intraperitoneal insulin delivery. Metabolism 43: 665-669, 1994.
50. Bagdade JD, Subbaiah PV, Ritter M, Dunn FL: Intraperitoneal insulin delivery normalizes cholesteryl ester transfer in IDDM. Diabetes 40(suppl. 1): 269A, 1991. (Abstract)
51. Georgopoulos A, Saudek CD: Intraperitoneal insulin delivery decreases the levels of chylomicron remmants in patients with IDDM. Diabetes Care 17: 1295-1299, 1994.
52. Colette C, Pares-Herbute N, Monnier L, Selam JL, Thomas N, Mirouze J: Effect of different insulin administration modalities on vitamin D metabolism of insulin-dependent diabetic patients. Horm Metab Res 21: 37-41, 1989.
53. Hanaire-Broutin H, Sallerin-Caute B, Poncet MF, et al: Insulin therapy and GU-IGF-I axis disorders in diabetes: impact of glycaemic control and hepatic insulinization. Diabet Metab 22: 245-450, 1996.
54. Lassmann-Vague V, Raccah D, Pugeat M, Bautrant D, Belicar P, Vague P: SHBG (Sex Hormone Binding Globulin) levels in insulin dependent diabetic patients according to the route of insulin administration. Horm Metab Res 26: 436-437, 1994.
55. Raccah D, Lassmann-Vague V, Alessi MC, Juhan-Vague I, Vague P: Intraperitoneal insulin administration does not modify plasminogen activator inhibitor 1 levels in IDDM patients. Diabetes Care 17: 941-942, 1994.
56. Renard E, Baldet P, Picot MC, et al: Catheter complications associated with implantable systems for peritoneal insulin delivery. Diabetes Care 18: 300-306, 1995.
57. Selam JL, Slingeneyer A, Chaptal PA, Franetzki M, Perstele K, Mirouze J: Total implantation of remotely controlled insulin minipump in a human insulin-dependent diabetic. Artif Organs 6: 315-319, 1982.
58. Dunn L, Nathan M, Scavini M, Selam JL, Wingrove T. for the Implantable Insulin Pump Trial Study Group: Long-term therapy of IDDM with an implantable insulin pump. Diabetes Care (in press).
59. The POINT study II group: Multicentre trial of a programmable implantable insulin pump in type I diabetes. Int J Artif Organs 18: 322-325, 1995.
60. Hanaire-Broutin H, Boussolle C, Jean-Didier N, et al: The EVADIAC Study Group: Feasibility of intraperitoneal insulin therapy with programmable implantable pumps in IDDM. Diabetes Care 18: 388-392, 1995.
61. Haardt MK, Selam JL, Slama G, et al: A cost-benefit comparison of intensive diabetes management with implantable pumps versus multiple subcutaneous injections in patients with type 1 diabetes. Diabetes Care 17: 847-851, 1994.
62. Broussolle C, Jean-Didier N, Hanaire-Broutin H. French multicentre experience of implantable insulin pumps. Lancet 343: 514-515, 1994.
63. Jean-Didier N, Selam JL, Renard E, et al: Decreased severe hypoglycemia frequency during intraperitoneal insulin infusion using programmable implantable pumps. Diabetes Care 19: 780, 1996.
64. C Saudek: U.S. VA Trial Results. ISGIID 1996, Septenber 12, 13, 1996, Meadowood, California.
65. Jean-Didier N, Boivin S, Buckenmeyer V, Sapin R, Pinget M: Five cases of hyperthyroidism in type I diabetic patients treated with intraperitoneal insulin infusion. Diabetes Care 18: 888-889, 1995.
66. Lassmann-Vague V, Belicar P, Sanmarco M, Carayon P, Alessis C, Vague Ph: Doest treatment by implanted pumps induce a general immune response in IDD patients? Horm Metab Res 28:23, 1996. (Abstract)
67. Jean-Didier N, Boivin S, Sapin R, et al: Immunogenicity of intraperitoneal insulin infusion using programmable implantable devices. Diabetologia 38: 577-584, 1995.
68. Olsen CL, Chan E, Turner DS, et al: Insulin antibody responses after long-term intraperitoneal insulin administration via implantable programmable insulin delivery systems. Diabetes Care 17: 169-176, 1994.
69. Lassmann-Vague V, Belicar P, Raccah D, Vialettes B, Sodoyez JC, Vague P: Immunogenicity of long-term intraperitoneal insulin administration with implantable programmable pumps. Diabetes Care 18: 498-503, 1995.